Tier 3 — preclinical

Effects of quercetin and its derivatives in in vivo models of neuroinflammation: A systematic review and meta-analysis

Michele Goulart Dos Santos, Bruno Dutra Arbo, Mariana Appel Hort
Neural regeneration research 2026 21(5):1783-1792

Bibliography

PubMed
PMID 40145967
PubMed Central
PMC12694622
DOI
10.4103/NRR.NRR-D-24-01175
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: The authors declare no conflicts of interest.

Study snapshot

DesignSystematic review and meta-analysis of animal neuroinflammation studies
ModelPreclinical evidence synthesis
Sample11 preclinical studies
InterventionQuercetin or derivatives in lipopolysaccharide-induced models
DurationExperiment-specific treatment periods
EndpointsInflammatory measures

What the study showed, in plain terms

Published in 2026, this source examined brain, cognition and sleep. Design: Systematic review and meta-analysis of animal neuroinflammation studies. Sample/model: 11 preclinical studies. The exposure or intervention was Quercetin or derivatives in lipopolysaccharide-induced models. Follow-up or treatment period: Experiment-specific treatment periods.

Pooled cytokine and microglial outcomes favored quercetin-related interventions.

Average methodological quality was modest and reporting often unclear. These animal findings do not establish relief of human brain fog or neurodegenerative disease.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Brain Fog, Memory and Sleep: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Pooled cytokine and microglial outcomes favored quercetin-related interventions.
  • The recorded outcome domains were Inflammatory measures.
  • The result applies to the tested exposure: Quercetin or derivatives in lipopolysaccharide-induced models; Experiment-specific treatment periods.

What this study can and cannot tell us

  • Average methodological quality was modest and reporting often unclear. These animal findings do not establish relief of human brain fog or neurodegenerative disease.
  • Cell concentrations, species, disease models and experimental routes cannot be converted directly into an effective or safe oral human regimen.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 3
Effects of quercetin in preclinical models of Parkinson's disease: A systematic review
Camila de Oliveira Vian et al. · Basic & clinical pharmacology & toxicology · 2024
Tier 3
Quercetin in Animal Models of Alzheimer's Disease: A Systematic Review of Preclinical Studies
Xiao-Wen Zhang et al. · International journal of molecular sciences · 2020

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology